.jpeg)
{{ variable.name }}
Triumeq is a fixed-dose combination antiretroviral drug consisting of the integrase strand transfer inhibitor (INSTI) dolutegravir and two nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine.
1. Generic name :Abacavir/Dolutegravir/Lamivudine (Abacavir/Dolutegravir/Lamivudine)
2. Trade name :Tri umeq® (Suimeikai)
3. Dosage form : Film-coated tablets
4. Main ingredients : Each tablet contains 600 mg of abacavir sulfate (equivalent to 600 mg of abacavir), 50 mg of dolutegravir sodium (equivalent to 50 mg of dolutegravir), and 300 mg of lamivudine. Excipients include D-mannitol, magnesium stearate, microcrystalline cellulose, etc.
1. HIV-1 infection : Suitable for the treatment of HIV-1 infection in adults.
2. Restricted use of : It is not recommended for patients with a history of resistance to abacavir, dolutegravir or lamivudine, or patients with suspected integrase strand transfer inhibitor (INSTI) resistance.
1. Specifications : Each tablet contains 600 mg of abacavir, 50 mg of dolutegravir, and 300 mg of lamivudine.
2. Characteristics : Purple oval film-coated tablet, with "572Trı" logo engraved on one side.
1. Recommended dosage of : Adults take 1 tablet per day, orally.
2. Taking time : Can be taken with food or on an empty stomach.
3. Treatment of missed doses : If you miss a dose, you should take it as soon as possible; if it is close to the next dose time (within 4 hours), skip the missed dose and take the medication as originally planned.
4. Special dose adjustment : When used in combination with efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir or rifampicin, an additional 50 mg of dolutegravir (interval 12 hours) is required.
1. Renal insufficiency : Not recommended for patients with creatinine clearance (CrCl) <50mL/min.
2. Hepatic insufficiency : No dose adjustment is required for mild hepatic insufficiency (Child-Pugh A grade); it is contraindicated for moderate to severe hepatic insufficiency (Child-Pugh B/C grade).
1. Allergic reaction : Abacavir may cause severe allergic reactions, and those carrying the HLA-B*5701 allele are at a higher risk. Genetic screening is required before medication.
2. Influence of diet : Can be taken with food, but avoid taking it with antacids containing aluminum/magnesium (an interval of 2 hours is required).
3. Vomiting treatment : If you vomit after taking the medicine, there is no need to take a supplement, and you can take the medicine next time as originally planned.
4. Medication packaging : Avoid swallowing the aluminum foil packaging by mistake. Take out the tablets before taking them.
1. Pregnant women : Use only when the potential benefits outweigh the risks (pregnancy grade C).
2. Lactation : Breastfeeding is prohibited.
3. Children : Safety has not been established.
4. Elderly : The dosage needs to be adjusted according to renal function.
1. Common (≥2%) : Insomnia (3%), headache (2%), fatigue (2%).
2. Severe reactions : Allergic reaction, lactic acidosis, exacerbation of hepatitis, myocardial infarction (rare).
1. Positive HLA-B*5701 allele or history of allergy to abacavir.
2. Combined use of dofetilide (TIKOSYN®).
3. Moderate to severe liver insufficiency.
1. Contraindicated use of : Dofetilide (risk of arrhythmia).
2. The dose of needs to be adjusted: When used in combination with rifampin and efavirenz, the dose of dolutegravir needs to be increased.
3. Affects the absorption of : Aluminium/magnesium-containing antacids and iron/calcium supplements need to be taken 2 hours apart.
1. Store in original packaging, moisture-proof, and avoid removing desiccant.
2. Storage temperature: 25°C (short-term fluctuations of 15°-30°C are allowed).
Note : Liver function, kidney function and HIV viral load need to be monitored regularly during treatment. When symptoms of allergic reaction occur, you need to stop taking the medicine immediately and seek medical advice.